Ardian acquired a majority stake in Neopharmed Gentili from its founding parent company, Mediolanum Farmaceutici. The Del Bono family, founders of Mediolanum, retained a 20% minority stake in the business to ensure operational and clinical continuity. The transaction was structured to provide the group with the capital and global network necessary to transition from a national champion to an international specialty pharma platform. The investment thesis centered on using Neopharmed's robust Italian sales network as a foundation for an aggressive "buy-and-build" strategy, targeting both product portfolios and strategic corporate acquisitions across Europe.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 13.4x since the beginning of 2026, 1.2% decrease compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.